HNN3.0

Project cooperationUpdated on 22 January 2026

Immunoadsorption (IA) for management of post-infection long-term conditions

Scientific Director - Grants and Collaborations @ R&D Department at Miltenyi Biotec

Bergisch Gladbach, Germany

About

Immunoadsorption (IA) with Miltenyi’s LIFE 21 TheraSorb Apheresis platform is already used in clinical trials to treat Post Covid ME/CFS (e.g. NCT05629988 or NCT05710770). These therapies are based on the selective removal of pathogenic substances such as immunoglobulins from the patient’s plasma with our specific adsorbers.

We are aiming to participate in European collaborative projects to further explore the potential benefits of immunoadsorption for the management of post-infection long-term conditions. Miltenyi’s Therasorb technology is ready for clinical use and we would like to contribute to new initiatives to facilitate broad patient access to this promising therapeutic approach in Europe.

Additional Information is available on Miltenyi’s homepage:

Studies | Immunoadsorption | TheraSorb | Miltenyi Biotec | Deutschland

Therasorb immunoadsorption COVID | Miltenyi Biotec | Deutschland

Topic

  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions

Type

  • Partner seeks Consortium/Coordinator

Organisation

Miltenyi Biotec

Company (Industry)

Bergisch Gladbach, Germany

Similar opportunities